Anhui Huaren Health Pharmaceutical Co., Ltd. (SHE:301408)
China · Delayed Price · Currency is CNY 17.72
+0.90 (5.35%)
At close: May 29, 2026
SHE:301408 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 5,532 | 5,378 | 4,454 | 3,723 | 3,202 | 2,269 |
Other Revenue | 109.13 | 109.13 | 77.81 | 74.42 | 60.74 | 69.46 |
| 5,641 | 5,487 | 4,532 | 3,797 | 3,262 | 2,339 | |
Revenue Growth (YoY) | 20.17% | 21.07% | 19.34% | 16.39% | 39.50% | 21.12% |
Cost of Revenue | 3,717 | 3,637 | 3,066 | 2,642 | 2,205 | 1,526 |
Gross Profit | 1,924 | 1,850 | 1,466 | 1,155 | 1,057 | 812.4 |
Selling, General & Admin | 1,447 | 1,404 | 1,190 | 961.8 | 807.26 | 687.3 |
Research & Development | 32.62 | 29.58 | 29.39 | 24.19 | 4.17 | 0.5 |
Other Operating Expenses | 18.61 | 16.52 | 8.69 | 5.66 | 17.16 | 13.02 |
Operating Expenses | 1,512 | 1,465 | 1,228 | 993.91 | 829.62 | 705.21 |
Operating Income | 411.41 | 384.69 | 237.65 | 161.47 | 227.66 | 107.19 |
Interest Expense | -30.8 | -30.22 | -32.15 | -29.05 | -23.38 | -24.03 |
Interest & Investment Income | 13.37 | 15.06 | 17.18 | 14.84 | 5.09 | 2.77 |
Currency Exchange Gain (Loss) | -0.13 | -0.13 | 0.11 | 0.1 | - | - |
Other Non Operating Income (Expenses) | -6.41 | -6.75 | -9.29 | -6.79 | -7.74 | -2.73 |
EBT Excluding Unusual Items | 387.43 | 362.64 | 213.49 | 140.56 | 201.63 | 83.21 |
Impairment of Goodwill | -72.11 | -72.11 | -17.2 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | 0.03 | - | - |
Gain (Loss) on Sale of Assets | 4.06 | 3.74 | 2.72 | 1.04 | 0.61 | 0.19 |
Asset Writedown | 3.06 | -0.04 | -0.01 | 0 | -0.01 | -0.02 |
Other Unusual Items | -0.81 | 0.17 | 6.47 | 9.87 | 12.51 | 10.84 |
Pretax Income | 321.62 | 294.39 | 205.47 | 151.51 | 214.74 | 94.22 |
Income Tax Expense | 86.76 | 80.52 | 53.21 | 33.83 | 54.48 | 24.48 |
Earnings From Continuing Operations | 234.87 | 213.87 | 152.26 | 117.68 | 160.26 | 69.73 |
Minority Interest in Earnings | -25.39 | -22.51 | -14.56 | -3.01 | 0.52 | -0.01 |
Net Income | 209.47 | 191.35 | 137.7 | 114.67 | 160.78 | 69.73 |
Net Income to Common | 209.47 | 191.35 | 137.7 | 114.67 | 160.78 | 69.73 |
Net Income Growth | 38.59% | 38.96% | 20.09% | -28.68% | 130.58% | -21.58% |
Shares Outstanding (Basic) | 399 | 399 | 405 | 395 | 342 | 332 |
Shares Outstanding (Diluted) | 399 | 399 | 405 | 395 | 342 | 332 |
Shares Change (YoY) | -1.55% | -1.57% | 2.43% | 15.59% | 3.02% | -2.92% |
EPS (Basic) | 0.53 | 0.48 | 0.34 | 0.29 | 0.47 | 0.21 |
EPS (Diluted) | 0.53 | 0.48 | 0.34 | 0.29 | 0.47 | 0.21 |
EPS Growth | 40.77% | 41.18% | 17.24% | -38.30% | 123.81% | -19.23% |
Free Cash Flow | 641.72 | 681.76 | 408.33 | -89.64 | 69.07 | 106.91 |
Free Cash Flow Per Share | 1.61 | 1.71 | 1.01 | -0.23 | 0.20 | 0.32 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | - | - |
Gross Margin | 34.10% | 33.71% | 32.34% | 30.43% | 32.41% | 34.74% |
Operating Margin | 7.29% | 7.01% | 5.24% | 4.25% | 6.98% | 4.58% |
Profit Margin | 3.71% | 3.49% | 3.04% | 3.02% | 4.93% | 2.98% |
Free Cash Flow Margin | 11.38% | 12.43% | 9.01% | -2.36% | 2.12% | 4.57% |
EBITDA | 456.8 | 429.03 | 277.81 | 182.91 | 240.37 | 267.85 |
EBITDA Margin | 8.10% | 7.82% | 6.13% | 4.82% | 7.37% | 11.45% |
D&A For EBITDA | 45.38 | 44.34 | 40.17 | 21.45 | 12.71 | 160.66 |
EBIT | 411.41 | 384.69 | 237.65 | 161.47 | 227.66 | 107.19 |
EBIT Margin | 7.29% | 7.01% | 5.24% | 4.25% | 6.98% | 4.58% |
Effective Tax Rate | 26.97% | 27.35% | 25.90% | 22.33% | 25.37% | 25.99% |
Revenue as Reported | 5,641 | 5,487 | 4,532 | 3,797 | 3,262 | 2,339 |
Advertising Expenses | - | 37.37 | 25.19 | 21.36 | 17.99 | 5.27 |